Fig. 3
A. MDA-MB-231 oxygen consumption rates (OCR (pmol/min)) vs. time after injection of (i) treatment or DMSO (ii) oligomycin (iii) FCCP and (iv) Rotenone and Antimycin A after treatment with IMD-0354 (1.25-0.078125µM). B. Calculated OCR subtracting non-mitochondrial respiration from OCR after oligomycin of DMSO control and after acute IMD-0354 injection (1.25-0.078125µM) indicating proton leak in MDA-MB-231 cells. C. Maximal respiration OCR of DMSO control and after treatment with IMD-0354 (1.25-0.078125µM) in MDA-MB-231 cells. D. Spare respiratory capacity OCR from subtracting OCR before oligomycin injection from maximal respiration after treatment with IMD-0354 (1.25-0.078125µM) in MDA-MB-231 cells. E. 4T1 oxygen consumption rates (OCR (pmol/min)) vs. time after injection of (i) treatment or DMSO (ii) oligomycin (iii) FCCP and (iv) Rotenone and Antimycin A after treatment with IMD-0354 (1.25-0.078125µM). F. Calculated OCR subtracting non-mitochondrial respiration from OCR after oligomycin of DMSO control and after acute IMD-0354 injection (1.25-0.078125µM) indicating proton leak in 4T1 cells. G. Maximal respiration OCR of DMSO control and after treatment with IMD-0354 (1.25-0.078125µM) in 4T1 cells. H. Spare respiratory capacity OCR from subtracting OCR before oligomycin injection from maximal respiration after treatment with IMD-0354 (1.25-0.078125µM) in 4T1 cells. B,C,D,F,G,H: results are representative of 3 biological replicates experiments having a combined total of 15 technical replicates per group ± SEM. Statistical analysis was carried out via Dunnett’s one-way ANOVA compared to DMSO control (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)